Disease or Syndrome – Page 75

Sionna Therapeutics Raises $191 Million in Upsized IPO for Cystic Fibrosis Drug Development

9 months ago talkbio0Tagged Clinical Trials, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, IPO, NBD1, Proteins, Sionna, Stabilizer - function

Sionna Therapeutics, cystic fibrosis, IPO, CFTR protein, NBD1 stabilizers, Vertex Pharmaceuticals, clinical trials

GLP-1 Weight Loss Drugs Make Super Bowl Advertising Debut Amid Shifting Health Marketing Landscape

9 months ago talkbio0Tagged Epidemic, Glucagon-Like Peptide 1, Health care facility, Hims & Hers, Obesity, pharmaceutical marketing, Super Bowl ads, Weight-Loss Agents

GLP-1, Super Bowl ads, Hims & Hers, weight loss drugs, pharmaceutical marketing, healthcare advertising, obesity epidemic

NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease

9 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, Clustered Regularly Interspaced Short Palindromic Repeats, England, exagamglogene autotemcel, gene therapy, Nance-Horan syndrome, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution

Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval

Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs

9 months ago talkbio0Tagged biotech, Dosage Forms, IPOs, Kidney Diseases, Listings, Metsera, Nasdaq, Obesity

Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding

FDA Approves Axsome’s Symbravo for Rapid Migraine Relief

9 months ago talkbio0Tagged acute, Approved, Axsome Therapeutics', meloxicam, Migraine Disorders, rizatriptan, Symbravo, United States Food and Drug Administration

Symbravo, meloxicam, rizatriptan, FDA approval, acute migraine treatment, rapid-acting, Axsome Therapeutics

FDA Approves Axsome’s Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection

9 months ago talkbio0Tagged acute, Approved, meloxicam, Migraine Disorders, MoSEIC, rizatriptan, Symbravo, Technology, United States Food and Drug Administration

Symbravo, Axsome Therapeutics, FDA approval, acute migraine treatment, meloxicam, rizatriptan, MoSEIC technology

Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism

9 months ago talkbio0Tagged amsacrine/azacitidine/etoposide, biotech, IPO, IPOs, Market, Metsera, Obesity, Optimism, Precision Medicine, trends qualifier

Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends

2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes

10 months ago talkbio0Tagged Administration occupational activities, ambulatory care services, Artificial Intelligence, deal activity, digital health, expansion, Gene Modification, Health care facility, Pharmaceutical Services, regulatory environment, Transplant Registry Unified Management Program

AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration

Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment

10 months ago talkbio0Tagged AKAP9 protein, human, Clinical Equipoise, Clinical Trials, Pulmonary arterial hypertension, sotatercept-csrk, Winrevair

Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

10 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro